U.S. Capital Wealth Advisors LLC Lowers Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

U.S. Capital Wealth Advisors LLC lowered its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7.4% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 56,011 shares of the biopharmaceutical company's stock after selling 4,490 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in Alnylam Pharmaceuticals were worth $15,124,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the business. Bessemer Group Inc. grew its stake in Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 69 shares during the last quarter. GAMMA Investing LLC grew its stake in Alnylam Pharmaceuticals by 14.3% during the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock worth $166,000 after buying an additional 77 shares during the last quarter. Brighton Jones LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $243,000. Silvercrest Asset Management Group LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $1,151,000. Finally, Amalgamated Bank grew its stake in Alnylam Pharmaceuticals by 4.3% during the 1st quarter. Amalgamated Bank now owns 8,853 shares of the biopharmaceutical company's stock worth $2,390,000 after buying an additional 369 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded up $0.98 during midday trading on Wednesday, hitting $318.48. 493,413 shares of the stock were exchanged, compared to its average volume of 855,226. The stock's 50-day moving average price is $297.55 and its 200-day moving average price is $267.35. The stock has a market cap of $41.53 billion, a price-to-earnings ratio of -152.64 and a beta of 0.23. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $333.70. The company has a debt-to-equity ratio of 8.88, a quick ratio of 2.98 and a current ratio of 3.04.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The business's quarterly revenue was up 20.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.16) EPS. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on ALNY. BMO Capital Markets lifted their target price on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a research note on Tuesday, June 24th. Wall Street Zen upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday. Scotiabank lifted their target price on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research note on Monday, March 31st. Chardan Capital lifted their target price on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, Needham & Company LLC lifted their target price on Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-two have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $341.91.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 31,640 shares of the firm's stock in a transaction on Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the completion of the transaction, the chief executive officer owned 48,948 shares of the company's stock, valued at approximately $14,899,281.72. This trade represents a 39.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.